StockData
LENZ Therapeutics, Inc. logo

LENZ Therapeutics, Inc. (LENZ) income statement

LENZNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 9/3055% below fair value
$3.21−0.29 (-8.29%)

Close on Nov 18, 2026Market cap $100.86MP/E –Yield –

LENZ Therapeutics, Inc. income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin
86.9%
Operating margin
-631.7%
Net margin
-586.7%
Return on equity, FY2025
-33.6%

Financial strength

Current ratio
13.55
Debt to equity
–
Debt to assets
–
Cash to current liabilities
140.6%

Valuation

P/E ratio
–
Price to sales
4.70
Price to book
0.46
Dividend yield
–

See a number that looks wrong?